Medicine and Dentistry
Heart Failure
100%
Heart Failure with Reduced Ejection Fraction
38%
Heart Failure with Preserved Ejection Fraction
33%
Ejection Fraction
31%
Acute Decompensated Heart Failure
26%
Biological Marker
15%
Cohort Analysis
13%
Heart Left Ventricle Ejection Fraction
13%
Diabetes
13%
Diabetes Mellitus
12%
Hazard Ratio
12%
Quality of Life
11%
Prevalence
11%
Drug Therapy
9%
Congestive Heart Failure
9%
Chronic Kidney Disease
9%
Amino Terminal Sequence
9%
Brain Natriuretic Peptide
8%
Atrial Fibrillation
8%
ACE Inhibitor
6%
All Cause Mortality
6%
Combination Therapy
6%
Cardiomyopathy
6%
Body Mass Index
5%
Angiotensin Receptor Antagonist
5%
Growth Differentiation Factor 15
5%
Beta Adrenergic Receptor Blocking Agent
5%
Socioeconomic Status
5%
Cohort Effect
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
96%
Heart Failure with Reduced Ejection Fraction
35%
Acute Heart Failure
35%
Heart Failure with Preserved Ejection Fraction
23%
Biological Marker
21%
Empagliflozin
13%
All Cause Mortality
13%
Dipeptidyl Carboxypeptidase Inhibitor
11%
Prevalence
11%
Congestive Heart Failure
9%
Chronic Kidney Failure
8%
Angiotensin Receptor Antagonist
8%
Brain Natriuretic Peptide
8%
Cardiomyopathy
7%
Angiotensin
7%
Renin
7%
Isotopes of Potassium
7%
Beta Adrenergic Receptor Blocking Agent
7%
Placebo
7%
Cohort Study
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Hyperkalemia
6%
Atrial Fibrillation
6%
Growth Differentiation Factor 15
5%
Inflammation
5%
Diabetes Mellitus
5%
Symptom
5%
Interleukin 6
5%
Cause of Death
5%
Pathophysiology
5%
Aldosterone
5%
Mineralocorticoid Antagonist
5%
Keyphrases
Heart Failure
53%
Heart Failure with Preserved Ejection Fraction (HFpEF)
48%
Acute Heart Failure
31%
Patients with Heart Failure
29%
Heart Failure Hospitalization
14%
Reduced Ejection Fraction
13%
All-cause Mortality
12%
Asia
11%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
10%
Beta-blockers
10%
Angiotensin-converting Enzyme Inhibitor (ACEi)
9%
Type 1 Diabetes Mellitus (T1DM)
9%
Confidence Interval
9%
Empagliflozin
9%
Clinical Outcomes
9%
Kansas City Cardiomyopathy Questionnaire
8%
Chronic Kidney Disease
8%
Angiotensin Receptor Blockers
8%
Left Ventricular Ejection Fraction
8%
Atrial Fibrillation
8%
BIOSTAT-CHF
7%
Quality of Life
6%
Failure Data
6%
Biomarker Profile
6%
Preserved Ejection Fraction
6%
Comorbidity
5%
Asian Patients
5%
Socioeconomic Status
5%
Renin-angiotensin-aldosterone System Inhibitors
5%
Up-titration
5%
Hyperkalemia
5%